SHENZHEN, China, April 13 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS; http://www.htdsmedical.com/) announces that the company management is proceeding with the company Share Buyback Program as per the news of April 1 2010 in an effort to raise the value of the company security.
HTDS management plans to continue with the Program, using financing from sales of some of the company disposable assets. HTDS management is of opinion that this financing should be sufficient to raise the price of the security to true worth of HTDS and satisfy all shareholders and investors.
HTDS' management will advise the public on all new developments regarding the share reduction program and all other news related to the HTDS security.
HTDS CEO Terry Yuan said "It is my understanding that the HTDS team of Slavica Bio Chem and Collagena Skin Care did a wonderful job at the Business Expo and Shareholders Conference. Unfortunately, I was unable to attend to meet and greet many HTDS shareholders that came by the HTDS booth. A soon to be contract announcement will explain why I needed to focus all my attention on bringing that contract to a fruition. It is my understanding that a group from USA will be visiting Slavica Bio Chem in Serbia for discussions and cooperation's on some of the projects that division is working on at the end of April. The USA group is showing particular interest in the Slavica rejuvenated medical project (see Filing Nov 24) http://www.otcmarkets.com/otciq/ajax/showFinancialReportById.pdf?id=26604 and other medical work the team is engaged in. HTDS will report back shortly after the conclusion of the USA group due diligence is completed, and we as a company will report back to our followers the significant and positive outcome this will have on the entire HTDS organization."
The company reminds its shareholders and followers to monitor our IR company web site section "PRESS RELEASES AND FILINGS" TAB http://www.minamargroup.net/ for non newsworthy corporate updates.
For any matters relating to retail investor queries or to send the company or its IR a message please click on the "INVESTOR SUPPORT" TAB, or the direct link http://www.minamargroup.net/helpdesk.
Don't be a victim. Report a stock basher. The company is mindful that short sellers, the company competitors and stock bashers stalk small cap Pink Sheets listed companies with hidden agendas. Visit http://www.stockbasher.com/ and find out what criminal and civil actions the US authorities are taking against web sites like investorshub.com and other posters, and the remedies available to you as an individual investor.
Filings for this event are currently being reviewed and will be filed with Pink Sheets and Client Support section in due course. To be included in company's email database for press releases, industry updates, and non-weekly activity in the company that may or may not be news released, please subscribe or opt in mailer at http://www.minamargroup.com/updates.
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only, please contact [email protected]; For any corporate matters, please contact www.minamargroup.com/helpdesk
SOURCE Hard to Treat Diseases
Advertisement
HTDS management plans to continue with the Program, using financing from sales of some of the company disposable assets. HTDS management is of opinion that this financing should be sufficient to raise the price of the security to true worth of HTDS and satisfy all shareholders and investors.
Advertisement
HTDS' management will advise the public on all new developments regarding the share reduction program and all other news related to the HTDS security.
HTDS CEO Terry Yuan said "It is my understanding that the HTDS team of Slavica Bio Chem and Collagena Skin Care did a wonderful job at the Business Expo and Shareholders Conference. Unfortunately, I was unable to attend to meet and greet many HTDS shareholders that came by the HTDS booth. A soon to be contract announcement will explain why I needed to focus all my attention on bringing that contract to a fruition. It is my understanding that a group from USA will be visiting Slavica Bio Chem in Serbia for discussions and cooperation's on some of the projects that division is working on at the end of April. The USA group is showing particular interest in the Slavica rejuvenated medical project (see Filing Nov 24) http://www.otcmarkets.com/otciq/ajax/showFinancialReportById.pdf?id=26604 and other medical work the team is engaged in. HTDS will report back shortly after the conclusion of the USA group due diligence is completed, and we as a company will report back to our followers the significant and positive outcome this will have on the entire HTDS organization."
The company reminds its shareholders and followers to monitor our IR company web site section "PRESS RELEASES AND FILINGS" TAB http://www.minamargroup.net/ for non newsworthy corporate updates.
For any matters relating to retail investor queries or to send the company or its IR a message please click on the "INVESTOR SUPPORT" TAB, or the direct link http://www.minamargroup.net/helpdesk.
Don't be a victim. Report a stock basher. The company is mindful that short sellers, the company competitors and stock bashers stalk small cap Pink Sheets listed companies with hidden agendas. Visit http://www.stockbasher.com/ and find out what criminal and civil actions the US authorities are taking against web sites like investorshub.com and other posters, and the remedies available to you as an individual investor.
Filings for this event are currently being reviewed and will be filed with Pink Sheets and Client Support section in due course. To be included in company's email database for press releases, industry updates, and non-weekly activity in the company that may or may not be news released, please subscribe or opt in mailer at http://www.minamargroup.com/updates.
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only, please contact [email protected]; For any corporate matters, please contact www.minamargroup.com/helpdesk
SOURCE Hard to Treat Diseases
